Business

AstraZeneca Pharma India gets DCGI nod to import

By Administrator_ India

Capital Sands

Drug firm AstraZeneca Pharma India said it has received import and market permission from the Indian drug regulator for Selumetinib capsules.

The company has received the import and market permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg & 25 mg capsules, AstraZeneca Pharma India said in a regulatory filing.

The receipt of this permission paves way for the launch of Selumetinib 10 mg & 25 mg capsules in India, subject to the receipt of related statutory approvals and licenses, it added.

Selumetinib 10 mg & 25 mg capsules are indicated for the treatment of pediatric patients 3 years of age and older with neurofibromatosis type 1 and who have symptomatic, inoperable plexiform neurofibromas, it added.

Related posts
Business

PM Modi to visit Kedarnath-Badrinath today, tight security in place.

Prime Minister Narendra Modi will visit Kedarnath and Badrinath today during which he will inspect…
Read more
Business

Oil prices rise on supply woes.

Oil prices rose in early Asian trade on Wednesday, paring losses from the previous session, as…
Read more
Business

Oil Prices Rise to Near $90 as OPEC Cut Looms

Oil prices rose further on Tuesday as markets positioned for the biggest supply cut by OPEC since…
Read more
Newsletter
Become a Trendsetter
Sign up for Davenport’s Daily Digest and get the best of Davenport, tailored for you. [mc4wp_form id="729"]

Leave a Reply

Your email address will not be published. Required fields are marked *